In the laboratory, it has been reported that several new phosphorylated tau specificities, including p-tau 181, p-tau 217, and p-tau 231 [57–59], have been used by research scientists to assess tau and Aβ pathological process as the novel blood biomarkers for the potential clinical diagnostic method of AD. This evidence concerns the gene MAPT and Alzheimer disease.